<DOC>
	<DOCNO>NCT02936388</DOCNO>
	<brief_summary>Characterisation effect SIRT DSM-TACE local treatment option liver metastases patient advanced uveal melanoma respect progression-free survival exploratory comparison secondary endpoint regard application , activity , adverse effect impact quality life randomize study design .</brief_summary>
	<brief_title>Transarterial Radioembolisation Comparison Transarterial Chemoembolisation Uveal Melanoma Liver Metastasis</brief_title>
	<detailed_description>This randomized phase II trial evaluate effect transarterial radioembolisation yttrium-90 microspheres ( SIRT ) transarterial chemoembolisation cisplatin ( DSM-TACE ) patient liver metastasis due advance uveal melanoma term progression-free survival multiple secondary endpoint . Patients study arm A receive transarterial radioembolisation one time . Patients study arm B receive transarterial chemoembolisation every 4 6 week complete tumor devascularisation observe disease progression intolerable toxicity occur . At time local tumor progression patient offer treatment respectively ( either SIRT DSM-TACE ) part study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion Criteria ( main ) : ECOG Performance Status 0 , 1 2 Histologically cytologically confirm liver metastasis uveal melanoma At least one measurable lesion accord RECIST criterion v1.1 determine MRI ( contraindication MRI exist CT contrast medium allow ) Metastases side allow need treatment ( e.g . asymptomatic bone metastasis without indication radiation ) Prior treatment systemic anticancer therapy allow terminate ≥ 4 week prior study treatment start recovery toxicity achieve Surgery general hepatic surgery particular ( e.g . lobe resection , radiofrequency ablation ) prior study enrollment allow realize ≥ 4 week prior study enrollment recovery surgery achieve Exclusion Criteria ( main ) : Surgically treatable liver metastases Previous intraarterial hepatic treatment ( e.g . radioembolisation , chemoembolisation , intraarterial chemotherapy , isolate percutaneous hepatic perfusion ) Previous treatment external liver radiation Major intrahepatic occlusion portal vein and/or tumor infiltration portal vein Liver cirrhosis ChildPugh C Progressive liver failure Renale failure , bone marrow insufficiency , coagulopathy Uncontrolled severe medical condition could impair ability participate trial unstable cardiac disease uncontrolled infection Other malignancy and/or metastasis need treatment Current treatment anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>uveal melanoma</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>chemoembolisation</keyword>
	<keyword>radioembolisation</keyword>
</DOC>